Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Kathleen Moore MD
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of ABT-888 when administered using continuous versus intermittent dosing schedules with intravenous carboplatin, paclitaxel and bevacizumab using two different treatment regimens; or with intraperitoneal cisplatin and intravenous and intraperitonal paclitaxel and bevacizumab in women with newly diagnosed, previously untreated, epithelial ovarian, fallopian tube, or primary peritoneal cancer.
To determine the feasibility of these treatment regimens over four cycles in a 2-stage group sequential design once the MTD is established.
To assess the toxicity of these regimens using the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Women with newly diagnosed, previously untreated, epithelial ovarian, fallopian tube, or primary peritoneal cancer.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.